AVROBIO Inc
NASDAQ:TECX
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.0007
19.2
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one TECX stock under the Base Case scenario is 6.65 USD. Compared to the current market price of 18.28 USD, AVROBIO Inc is Overvalued by 64%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
AVROBIO Inc
Run backtest to discover the historical profit from buying and selling TECX based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
AVROBIO Inc
Balance Sheet Decomposition
AVROBIO Inc
Current Assets | 187.4m |
Cash & Short-Term Investments | 185.1m |
Other Current Assets | 2.3m |
Non-Current Assets | 6.5m |
PP&E | 5.9m |
Other Non-Current Assets | 600k |
Current Liabilities | 26m |
Accounts Payable | 4.1m |
Accrued Liabilities | 20.6m |
Other Current Liabilities | 1.4m |
Non-Current Liabilities | 1.5m |
Long-Term Debt | 637k |
Other Non-Current Liabilities | 905k |
Earnings Waterfall
AVROBIO Inc
Revenue
|
0
USD
|
Operating Expenses
|
-56m
USD
|
Operating Income
|
-56m
USD
|
Other Expenses
|
-2.2m
USD
|
Net Income
|
-58.3m
USD
|
Free Cash Flow Analysis
AVROBIO Inc
USD | |
Free Cash Flow | USD |
TECX Profitability Score
Profitability Due Diligence
AVROBIO Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
AVROBIO Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
TECX Solvency Score
Solvency Due Diligence
AVROBIO Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
AVROBIO Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TECX Price Targets Summary
AVROBIO Inc
According to Wall Street analysts, the average 1-year price target for TECX is 61.2 USD with a low forecast of 49.49 USD and a high forecast of 79.8 USD.
Shareholder Yield
Current shareholder yield for TECX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
TECX Price
AVROBIO Inc
Average Annual Return | 85.03% |
Standard Deviation of Annual Returns | 117.42% |
Max Drawdown | -33% |
Market Capitalization | 265.1m USD |
Shares Outstanding | 14 730 000 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of five lentiviral-based gene therapy programs, which include AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3, and AVR-RD-03 for the treatment of Pompe disease.
Contact
IPO
Employees
Officers
The intrinsic value of one TECX stock under the Base Case scenario is 6.65 USD.
Compared to the current market price of 18.28 USD, AVROBIO Inc is Overvalued by 64%.